Unlock breakthrough rare disease market insights fast
Access on-demand primary market research reports tailored to your business questions and delivered in as little as 15 days.
Get fresh primary market research-driven insights and answers to your most pressing business questions in 15 days or less
Unlock breakthrough market insights for any disease fast
Get fresh primary market research-driven insights and answers to your most pressing business questions in 15 days or less
Get fresh primary market research-driven insights and answers to your most pressing business questions in 15 days or less
OUR LIFE SCIENCES
MARKET RESEARCH SOLUTIONS
On-demand reports grounded in primary market research
Indication Prioritization
Market Primers →
MarketSheet reports are concise one-page indication summaries that enable triage of potential indications for product development
Market Assessment
Market Landscape →
MarketVue® reports capture the current and anticipated future state of a disease market
Epidemiology →
EpiVue® reports quantify and forecast patient populations
Custom
Rapid Insights →
Fast turnaround primary market research insights for a focused set of proprietary questions for physicians or payers
We specialize in niche markets, specifically rare diseases and subpopulations of common diseases.
We specialize in niche markets, specifically rare diseases and subpopulations of common diseases.
OUR DISEASE EXPERTISE
Pharmaceutical R&D is increasingly focused on niche markets such as rare diseases and subpopulations within common diseases. REACH is at the forefront of this exciting shift, specializing in delivering actionable market insights for these specific segments. Having conducted syndicated and custom market research for 192 rare diseases and subpopulations of common conditions, we are well-equipped to help life sciences professionals make strategic product development decisions in these dynamic markets.
Rare diseases
Characterized by low prevalence and limited drug development history, rare diseases present unique product development challenges that we deeply understand.
Niche subpopulations of common diseases
These subpopulations are often complex, treatment-resistant forms of prevalent diseases, sharing many of the product development challenges seen in rare disease markets.
OUR RESEARCH MODEL
Our senior pharmaceutical market researchers provide timely customizable market insights with a hands-on approach and uncompromising quality.
ON-DEMAND
Fresh market research is conducted upon request for any disease
FAST
New research and insights delivered in 15 days or less
PMR-DRIVEN
Insights informed by qualitative interviews and/or quantitative surveys
SENIOR TEAM
Experienced team members (10+ years in pharma market research) lead the research
CUSTOMIZABLE
Customizable research includes your questions and topics of interest
WHAT OUR CLIENTS ARE SAYING
It was great to see you at your market access pulse survey readout on Wednesday! The team’s feedback has been consistently very positive with the product quality, Melissa’s expertise, and the process getting the research completed on time. I’m so glad that [name] has you as an obvious go-to-choice for ad hoc requests for [our product].
For us, MarketVue® is very valuable to get fast reports and at the right level of detail. We were originally supposed to develop disease strategies but then we had a reorganization and resources were constrained. REACH is a great help to us.
Konstanze Binder
I need something beyond what I can do for myself with Google and without paying an extraordinary amount of money… MarketVue® goes even further — it’s not your typical syndicated report. It was very collaborative. REACH operates with the best aspects of primary research but then benefits like speed of syndicated reports.
Tony Russell
With MarketVue® reports, you can get 80-90% of output for 10% of the cost [of custom consulting] — this is great, especially for small clients like us whose budgets are tight, and we don’t have a ton of FTEs. I’m a team of 1. I can’t blow my whole budget on a single question.
Joe Pirrello
Regarding the [rare disease] development program related to our project before the break, I don’t recall if I ever relayed the message – folks were very complimentary of the supportive market research, so THANK YOU very much for a very successful and timely engagement. Let’s stay in touch over the coming weeks on any imminent projects that may materialize on our end.
Before even getting to the MarketVue® product, the process is a huge plus for them. The fact that we can get a tailored report with essentially a proprietary set of questions at that price range with that level of engagement with the team is hugely valuable and gives us a lot of trust with what we receive. MarketVue® is really high quality in general and comparable to much more expensive reports where you get a 100-page report — in terms of value for the amount we use it, it is comparable to much, much more expensive research… They’re really good at highlighting what is most relevant.
Julia Chornak
BTW – I wanted to tell you that the chatter with the [rapid insights] work you just delivered within our NPC team is that you killed it. So, I anticipate you will be our go to for much more work like this in the future.
REACH reports give you the ability to tailor the research a little bit more. I work in rare disease where [syndicated reports] just don’t exist and if they do, they’re not built out. For folks like myself, there is limited ability to use those off-the-shelf reports since they’re focused on mass market. I value the REACH team’s ability and willingness to answer follow up questions, dive in around specific topics, push back on the report, and think critically with us around the implications of the findings… I eventually asked them to synthesize all of our email back/forth into a separate report because I thought it was so useful and thoughtful.
Joe Pirrello
What pushed me over the edge was that they have a nice way of presenting the findings in the end. Sometimes you get a wall of text. Their output was very clean and useful for putting into our slides. I’ve worked with a lot of vendors, and it can be pretty hit or miss. Some vendors can be good at executing, but REACH can be a thought partner. They can take what we’re saying and riff off of us, then come up with additional ideas and put them in front of us.
Kathleen Davenport
Want to know more?
REACH out to our experts or subscribe to our complementary newsletter on rare and niche disease drug development strategy.